Daniel O'Day (AP Images)
In possible sign of things to come, Daniel O’Day’s new-look Gilead bets $4.9B on cancer biotech
Gilead has made its first big splash in three years, acquiring the cancer biotech Forty Seven for $4.9 billion, the drugmaker announced.
The biotech brings …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
